PERGINASE

*Acute Lymphocytic Leukaemia:* BY IV INJ: Adults & Children: 1000 IU/kg every day x 10 days beginning day 22 of treatment period or by IM, 6000 IU/m2 on days 4,7,10,13,16,19,22,25, & 28.

May be administered IV, IM, or SC. IM inj should be given as a deep into a large muscle. IV infusion in 50250 ml of D5W or NS over at least 60 min; a small test dose (0.1 ml of dilute 20 unit/ml solution) should be given first. Lyophilized powder should be reconstituted with 1-5 ml SWFI for IV administration or NS for IM use

Serious thrombosis, pancreatitis, history of pancreatitis related to asparaginase therapy

May alter hepatic function; use caution with pre-existing liver impairment. Monitor coagulation parameters; use cautiously in patients with underlying coagulopathy. May cause serious and possibly fatal pancreatitis; discontinue if severe abdominal pain develops. Used under medical supervision

Dexamethasone.

Coagulation disorders, confusion, convulsions, diarrhoea, dizziness, drowsiness, headache, lethargy, liver dysfunction, neurotoxicity, pancreatitis, anaphylaxis, changes in blood lipids, hyperglycaemia, alopecia, bone-marrow suppression, extravasation, hyperuricaemia, nausea, oral mucositis, thromboembolism, tumourlysis syndrome, vomiting, depression, myalgia, hypofibrinogenemia, decrease in number of clotting factors, hypotension, angioedema, bronchospasm, increased bilirubin, transaminases and alkaline phosphatase, azotemia, stomafifits